EU adds the pediatric indication and SURMOUNT-5 data to Mounjaro

On 22 January 2026, the European Commission signed off on two separate label changes for Mounjaro (tirzepatide) on the same day, according to the European Medicines Agency's procedural record for the medicine ^[1]. One change extends the approved indication to children and adolescents aged 10 years and older with type 2 diabetes. The other revises guidance on breastfeeding. Both variations share the same Commission Decision date, which is what the EMA record shows as the "single Commission decision date" covering more than one labeling update ^[1].

The pediatric extension is based on final results from a study identified in EMA records as I8F-MC-GPGV, also called SURPASS-PEDS, which evaluated the efficacy, safety, and pharmacokinetics and pharmacodynamics of tirzepatide in children and adolescents with type 2 diabetes whose blood sugar was not adequately controlled with metformin, basal insulin, or both ^[1]. As a result of this study, sections 4.1, 4.2, 4.8, 5.1, 5.2, and 5.3 of the Summary of Product Characteristics were updated, along with the package leaflet, and the company submitted an updated risk management plan ^[1].

The second change updates section 4.6 of the label, which covers breastfeeding, based on a separate study called GPIN (I8F-MC-GPIN), a small Phase 1 lactation study in healthy breastfeeding women ^[1]. After a single 5 mg dose, tirzepatide levels in breastmilk were undetectable to very low compared with levels in the mother's blood plasma, according to the EMA summary ^[1]. Because tirzepatide is a protein-like molecule, any small amount that did pass into breastmilk would be expected to break down and not be absorbed intact by a nursing infant, the agency noted ^[1]. The label was also updated to flag a theoretical indirect effect: tirzepatide can reduce a mother's food intake, which could alter breastmilk composition ^[1]. The EMA's overall conclusion states that tirzepatide "could be considered for use during breast-feeding" ^[1].

The sources reviewed for this story do not use the term "SURMOUNT-5" in connection with this 22 January 2026 decision. A separate, later variation in the same EMA document does reference a head-to-head trial — SURPASS-CVOT — which compared tirzepatide against dulaglutide on major cardiovascular events in people with type 2 diabetes, but that update carries a different timeline, tied to a decision dated around 25 June 2026 ^[1]. Whether a SURMOUNT-5 data package, which in public reporting elsewhere has referred to a tirzepatide-versus-semaglutide obesity comparison, was formally added to the Mounjaro label on 22 January 2026 is not confirmed in the EMA procedural record reviewed here.

Why it matters for patients

For families in the European Union, the pediatric extension means tirzepatide can now be prescribed on-label to children as young as 10 with type 2 diabetes who have not achieved control with standard treatments, based on the SURPASS-PEDS trial data reviewed by EMA ^[1]. The breastfeeding update gives EU prescribers and nursing mothers more specific information about drug exposure through breastmilk, rather than a blanket caution ^[1].

This is an EU regulatory action, not an FDA one. US patients on Mounjaro or Zepbound (also tirzepatide) will not see an automatic change to their US label from this EU decision. The FDA reviews its own data packages and sets its own labeling on separate timelines, so any pediatric or breastfeeding label changes in the United States would require independent FDA action not described in these sources.

What happens next

According to the EMA record, a separate variation adding cardiovascular outcomes data from the SURPASS-CVOT trial to the Mounjaro label is tied to a Commission Decision dated around 25 June 2026 ^[1]. Whether or how any SURMOUNT-5 style head-to-head efficacy data might be added to EU or US tirzepatide labeling is not addressed in the sources reviewed and is not yet known.